All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Full Approval to Selpercatinib for RET+ Thyroid Cancer

June 12th 2024

The FDA granted full approval to selpercatinib for select patients with advanced or metastatic RET fusion–positive thyroid cancer.

Decreases in ctDNA VAF Tied to Improved CBR With Imlunestrant in Pretreated ER+/HER2– Advanced Breast Cancer

June 12th 2024

Decreases in variant allele frequency in ctDNA were linked to improved CBR with imlunestrant in estrogen receptor–positive, HER2-negative breast cancer

Mahdi Taha, DO, FACOI, FACP is Lead Author of Case Study Demonstrating Importance of Genomic Testing in Early identification and Treatment of Cancer

June 12th 2024

A case study details the importance of genomic testing in identifying cancer and guiding targeted treatment decisions that enhance overall survival.

NGC-Cap Demonstrates Preliminary Efficacy in Stage III/IV GI Cancer

June 12th 2024

Next generation capecitabine led to positive preliminary efficacy results in patients with stage III or IV gastrointestinal tract cancer.

Emavusertib Represents Safe, Manageable IRAK4 Inhibitor in FLT3- and Splicing Factor–Mutated AML

June 12th 2024

Eric Winer, MD, discusses the safety and efficacy outcomes of the TakeAim Leukemia trial and future research with emavusertib in combination therapies.

Versamune HPV Plus Pembrolizumab Maintains Encouraging OS in Recurrent/Metastatic HPV16+ HNSCC

June 12th 2024

Versamune HPV in combination with pembrolizumab produced a durable median overall survival in patients with recurrent or metastatic HPV16-positive HNSCC.

Frontline Toripalimab Plus Bevacizumab Improves PFS, OS in Advanced HCC

June 12th 2024

Frontline toripalimab plus bevacizumab improved progression-free survival and overall survival vs sorafenib in patients with advanced hepatocellular carcinoma.

Hypofractionation is Noninferior to Conventional Fractionation Radiotherapy in Low-Risk Prostate Cancer

June 12th 2024

Hypofractionation radiotherapy was noninferior to conventional fractionation radiotherapy for the treatment of patients with low-risk prostate cancer.

Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies

June 12th 2024

Talquetamab proved safe and effective for relapsed/refractory myeloma, even in patients with comorbidities.

Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC

June 11th 2024

Clinical benefit generated from treatment with lurbinectedin plus irinotecan was noted across sensitive and resistant patient populations with SCLC.

Long-Term Data for Up-Front Combinations Reaffirm Treatment Options in CLL

June 11th 2024

Kathleen A. Dorritie, MD, discusses long-term data from trials in chronic lymphocytic leukemia presented at the 2023 ASH Annual Meeting.

Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC

June 11th 2024

The strength of mKRAS-specific T-cell responses produced by ELI-002 7P correlated with tumor biomarker responses in pancreatic and colorectal cancer.

Frontline Camrelizumab/Rivoceranib Prolongs OS vs Sorafenib in Unresectable HCC

June 11th 2024

Arndt Vogel, MD, discusses the updated OS analysis of CARES-310, as well as future directions for rivoceranib plus camrelizumab in unresectable HCC.

Temple University Hospital and Fox Chase Researchers Investigate Survival Outcomes Following Adjuvant Treatment in Clinical T2N0 Rectal Cancer Patients

June 11th 2024

A study from researchers at Temple University Hospital and Fox Chase Cancer Center found that adjuvant therapy may be underutilized in T2N0 rectal cancer.

UV1 Cancer Vaccine as a Pembrolizumab Add-On Continues to Strengthen OS in Melanoma

June 11th 2024

UV1 added to pembrolizumab elicited sustained OS outcomes as frontline therapy in advanced, unresectable, or metastatic malignant melanoma.

Maughan Spotlights Ways to Reengage the Immune System and Debulking Approaches in RCC

June 11th 2024

Benjamin L. Maughan, MD, PharmD, highlights ongoing research regarding the role of cytoreductive nephrectomy and targeted therapies in RCC.

Enhancing the Referral Process for Genetic Testing Represents Key Next Step in Breast Cancer

June 11th 2024

Brittany Bychkovsky, MD, MSc, discusses the role of genetic testing in breast cancer care and explores approaches to improving the testing process.

CDK9 Inhibitor SLS009 Displays Activity in Relapsed/Refractory AML

June 10th 2024

Enrollment of patients in a phase 2 study evaluating SLS009 in relapsed/refractory AML has been completed and the agent demonstrated initial efficacy.

SL-172154 Receives FDA Orphan Drug Designation in AML

June 10th 2024

SL-172154 has been granted orphan drug designation from the FDA in acute myeloid leukemia.

Roswell Park Experts Launch Comprehensive Lung Cancer Screening List for New York State

June 10th 2024

To improve access to lung cancer screening, Roswell Park Comprehensive Cancer Center experts have launched an online provider registry.